Vertex Presents Updated VX-880 Results From Ongoing Phase 1/2 Study In Type 1 Diabetes
Portfolio Pulse from Benzinga Newsdesk
Vertex Pharmaceuticals has presented updated results from its ongoing Phase 1/2 study of VX-880 in Type 1 Diabetes. The two patients with at least 1 year of follow-up met the primary endpoint of elimination of severe hypoglycemic events and HbA1c <7.0%. All patients treated with VX-880 have demonstrated islet cell engraftment and glucose-responsive insulin production.
October 03, 2023 | 10:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from the ongoing Phase 1/2 study of VX-880 in Type 1 Diabetes could potentially boost Vertex's stock in the short term.
The positive results from the ongoing study indicate that the drug VX-880 is effective in treating Type 1 Diabetes. This could potentially lead to regulatory approval and commercialization, which would increase Vertex's revenues and potentially its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100